MarketCapExport financials
Utah Medical Products (UTMD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Utah Medical Products Cash Flow 2025-2008 | UTMD
Brief overview of Utah Medical Products's cash flow quality
The review uses the five latest available annual reports between 2021 and 2025.
Cash from operations fell 30.7%, from $21.2 million to $14.7 million. The direction warrants attention.
Five positive readings out of five point to good predictability in operating cash generation.
Operating cash margin was stable at 164.2% initially and 162.5% at the end.
Overall picture
Utah Medical Products's cash flows are broadly resilient, though selected ratios need monitoring. Positive earnings conversion and moderate investment demand remain important.
Annual Cash Flow Utah Medical Products
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
14.7 M | 14.8 M | 22.3 M | 21.1 M | 21.2 M | 20.1 M | 17.1 M | 16.8 M | 16.9 M | 14.5 M | 13.8 M | 15.4 M | 12.3 M | 13.6 M | 11.4 M | 7.16 M | 7.23 M | - |
Depreciation & Amortization |
826 K | 730 K | 623 K | 612 K | 636 K | 655 K | 700 K | 765 K | 660 K | 610 K | 619 K | 637 K | 611 K | 653 K | 707 K | 563 K | 555 K | - |
Accounts Payables |
911 K | 696 K | 769 K | 1.22 M | 761 K | 788 K | 1.1 M | 975 K | 934 K | 906 K | 649 K | 929 K | 773 K | 1 M | 925 K | 398 K | - | - |
Accounts Receivables |
3.52 M | 4.09 M | 3.39 M | 5.54 M | 5.13 M | 4.1 M | 4.74 M | 3.96 M | 3.62 M | 3.21 M | 4.56 M | 4.7 M | 4.34 M | 4.34 M | 4.73 M | 3.16 M | - | - |
Total Inventories |
7.94 M | 8.81 M | 9.58 M | 8.81 M | 6.6 M | 6.22 M | 6.91 M | 5.41 M | 5.24 M | 4.54 M | 4.2 M | 4.87 M | 4.7 M | 4.35 M | 5 M | 3.1 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow Utah Medical Products
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | 3.11 M | - | - | - | 4.46 M | - | - | - | 5.28 M | - | - | - | 6.92 M | - | 15.5 M | 9.88 M | 5.05 M | - | 16.2 M | 10.2 M | 5.53 M | - | 14.4 M | 9.35 M | 5.67 M | - | 11.4 M | 5.04 M | 3.36 M | - | 12.4 M | 7.75 M | 3.77 M | - | 12.3 M | 7.74 M | 4.31 M | - | 11.1 M | 7.76 M | 4.15 M | - | 9.9 M | 5.73 M | 2.24 M | - | 10.9 M | 5.76 M | 1.92 M | - | 9.06 M | 5.04 M | 2.72 M | - | 10.5 M | 6.54 M | 3.43 M | - | 7.86 M | 4.45 M | 2.76 M |
Depreciation & Amortization |
- | 211 K | - | - | - | 200 K | - | - | - | 156 K | - | - | - | 155 K | - | 454 K | 302 K | 149 K | - | 483 K | 325 K | 163 K | - | 495 K | 335 K | 175 K | - | 526 K | 355 K | 179 K | - | 577 K | 395 K | 200 K | - | 489 K | 330 K | 166 K | - | 452 K | 298 K | 149 K | - | 461 K | 301 K | 149 K | - | 474 K | 311 K | 156 K | - | 459 K | 308 K | 155 K | - | 494 K | 334 K | 820 K | - | 536 K | 354 K | 265 K |
Accounts Payables |
911 K | 1.19 M | 696 K | 768 K | 737 K | 914 K | 696 K | 999 K | 834 K | - | 769 K | 511 K | 1.34 M | 1.03 M | 1.22 M | 1.29 M | 818 K | 1.45 M | 761 K | 1.03 M | 1.19 M | 839 K | 788 K | 788 K | 788 K | 788 K | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 975 K | 975 K | 975 K | 975 K | 934 K | 934 K | 934 K | 934 K | 906 K | 906 K | 906 K | 906 K | 649 K | 649 K | 649 K | 649 K | 929 K | 929 K | 929 K | 929 K | 773 K | 773 K | 773 K | 773 K | 1 M | 1 M | 1 M | 1 M | 925 K | 925 K | 925 K | 925 K |
Accounts Receivables |
3.52 M | 3.64 M | 4.09 M | 3.72 M | 3.63 M | 3.94 M | 4.09 M | 3.72 M | 3.67 M | - | 3.39 M | 3.49 M | 3.6 M | 3.82 M | 5.54 M | 6.03 M | 4.94 M | 5.72 M | 5.13 M | 4.85 M | 4.61 M | 4.16 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.74 M | 4.74 M | 4.74 M | 4.74 M | 3.96 M | 3.96 M | 3.96 M | 3.96 M | 3.62 M | 3.62 M | 3.62 M | 3.62 M | 3.21 M | 3.21 M | 3.21 M | 3.21 M | 4.56 M | 4.56 M | 4.56 M | 4.56 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.34 M | 4.34 M | 4.34 M | 4.34 M | 4.34 M | 4.34 M | 4.34 M | 4.34 M | 4.73 M | 4.73 M | 4.73 M | 4.73 M |
Total Inventories |
7.94 M | 8.72 M | 8.81 M | 8.12 M | 8.23 M | 8.65 M | 8.81 M | 9.11 M | 9.06 M | - | 9.58 M | 9.71 M | 10.1 M | 9.94 M | 8.81 M | 8.31 M | 7.34 M | 7.37 M | 6.6 M | 6.3 M | 6.12 M | 5.98 M | 6.22 M | 6.22 M | 6.22 M | 6.22 M | 6.91 M | 6.91 M | 6.91 M | 6.91 M | 6.91 M | 5.41 M | 5.41 M | 5.41 M | 5.24 M | 5.24 M | 5.24 M | 5.24 M | 4.54 M | 4.54 M | 4.54 M | 4.54 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 4.87 M | 4.87 M | 4.87 M | 4.87 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.35 M | 4.35 M | 4.35 M | 4.35 M | 5 M | 5 M | 5 M | 5 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Utah Medical Products, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical instruments sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
$ 38.61 | 3.51 % | $ 1.84 B |  USA |
 |
Becton, Dickinson and Company
BDX
|
$ 194.34 | 0.3 % | $ 55.9 B | USA |
 |
Alcon
ALC
|
$ 67.43 | -0.58 % | $ 33.3 B |  Schweiz |
 |
Intuitive Surgical
ISRG
|
$ 428.12 | -2.26 % | $ 153 B | USA |
 |
Repro Med Systems
KRMD
|
$ 3.11 | 2.3 % | $ 144 M | USA |
 |
AtriCure
ATRC
|
$ 57.67 | -0.23 % | $ 2.75 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Milestone Scientific
MLSS
|
$ 0.31 | -8.31 % | $ 25.4 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 91.4 | 0.24 % | $ 5.41 B | USA |
 |
Nephros
NEPH
|
$ 3.59 | 1.99 % | $ 38.1 M | USA |
 |
electroCore
ECOR
|
$ 7.35 | -1.87 % | $ 62.4 K | USA |
 |
Envista Holdings Corporation
NVST
|
$ 23.19 | 0.96 % | $ 3.9 B | USA |
 |
Baxter International
BAX
|
$ 24.7 | 0.78 % | $ 12.7 B | USA |
 |
Pro-Dex
PDEX
|
$ 60.56 | 1.96 % | $ 195 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 51.31 | 0.92 % | $ 3.46 B | USA |
 |
Repligen Corporation
RGEN
|
$ 180.01 | 0.63 % | $ 10.1 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.58 | -0.02 % | $ 17.4 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 21.61 | -3.18 % | $ 1.07 B | USA |
 |
STERIS plc
STE
|
$ 221.48 | -1.58 % | $ 21.7 B | USA |
 |
Stereotaxis
STXS
|
$ 0.99 | -0.34 % | $ 90 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 14.05 | -1.26 % | $ 290 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 176.85 | 1.97 % | $ 10.1 B | USA |
 |
AngioDynamics
ANGO
|
$ 11.89 | 0.68 % | $ 494 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 117.11 | -0.93 % | $ 5.53 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 393.48 | 1.21 % | $ 28.4 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 113.55 | -0.26 % | $ 3.63 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 83.67 | 0.32 % | $ 1.89 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 8.49 | 1.8 % | $ 377 M | USA |
 |
ICU Medical
ICUI
|
$ 160.84 | -0.15 % | $ 3.96 B | USA |
 |
ResMed
RMD
|
$ 246.2 | 0.31 % | $ 35.8 B | USA |
 |
OraSure Technologies
OSUR
|
$ 3.86 | 3.07 % | $ 284 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 9.08 | 2.37 % | $ 1.81 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 130.4 | -0.57 % | $ 5.82 B | USA |
 |
The Cooper Companies
COO
|
$ 58.97 | -0.25 % | $ 11.7 B | USA |
 |
Microbot Medical
MBOT
|
$ 0.94 | -0.78 % | $ 43 M |  Israel |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |